von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)1
Tóm tắt
Từ khóa
Tài liệu tham khảo
Association of Hemophilia Clinic Directors of Canada, 1995, Hemophilia and von Willebrand’s disease: 1. Diagnosis, comprehensive care and assessment, CMAJ, 153, 19
The National Heart, Lung, and Blood Institute, 2007, The Diagnosis, Evaluation and Management of Von Willebrand Disease
Eikenboom JC, 1998, Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin, Thromb Haemost, 79, 709, 10.1055/s-0037-1615050
ISTH, SSC VWF Database [Database on the Internet]
Sadler JE, 1994, Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease, Thromb Haemost, 71, 520, 10.1055/s-0038-1642471
Castaman G, 2003, Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment, Haematologica, 88, 94
Meyer D, 1997, INSERM Network on Molecular Abnormalities in von Willebrand Disease: gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene, Thromb Haemost, 78, 451, 10.1055/s-0038-1657568
Gavazova S, 2002, A mutation in the D4 domain of von Willebrand factor (VWF) results in a variant of type 1 von Willebrand disease with accelerated in vivo VWF clearance [abstract], Blood, 100, 128a
Lethagen S, 2002, Von Willebrand’s disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X), Thromb Haemost, 88, 421, 10.1055/s-0037-1613232
Schneppenheim R, 2000, Von Willebrand disease type 2M ‘Vicenza’ in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families, Thromb Haemost, 83, 136, 10.1055/s-0037-1613769
Mannucci PM, 1989, Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease, Blood, 74, 2433, 10.1182/blood.V74.7.2433.2433
Gaucher C, 1994, Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease, Blood, 84, 1024, 10.1182/blood.V84.4.1024.1024
Kinoshita S, 1984, A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern of factor VIII‐related antigen (type IID), Blood, 63, 1369, 10.1182/blood.V63.6.1369.1369
Rick ME, 1987, Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand’s disease, Blood, 69, 786, 10.1182/blood.V69.3.786.786
Casonato A, 1990, 1‐Desamino‐8‐D‐arginine vasopressin (DDAVP) infusion in type IIB von Willebrand’s disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia, Thromb Haemost, 64, 117, 10.1055/s-0038-1647265
Kroner PA, 1992, Expressed full‐length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets, Blood, 79, 2048, 10.1182/blood.V79.8.2048.2048
Hillery CA, 1998, Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin‐ but not botrocetin‐mediated binding of von Willebrand factor to platelets, Blood, 91, 1572, 10.1182/blood.V91.5.1572
Mancuso DJ, 1996, Type 2M:Milwaukee‐1 von Willebrand disease: an in‐frame deletion in the Cys509‐Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets, Blood, 88, 2559, 10.1182/blood.V88.7.2559.bloodjournal8872559
Mazurier C, 1990, A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: characterization of abnormal vWF/FVIII interaction, Blood, 75, 20, 10.1182/blood.V75.1.20.20
Montgomery RR, 1982, A variant of von Willebrand’s disease with abnormal expression of factor VIII procoagulant activity, Blood, 60, 201, 10.1182/blood.V60.1.201.201
Mazurier C, 1996, Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease: results of an international survey, Thromb Haemost, 76, 270, 10.1055/s-0038-1650567
Schneppenheim R, 1996, Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1, Thromb Haemost, 76, 598, 10.1055/s-0038-1650628
Zhang ZP, 1992, Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I, Am J Hum Genet, 51, 850
Mannucci PM, 1981, Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: effects on replacement therapy, Blood, 57, 25, 10.1182/blood.V57.1.25.25
Mannucci PM, 1988, Von Willebrand disease ‘Vicenza’ with larger‐than‐normal (supranormal) von Willebrand factor multimers, Blood, 71, 65, 10.1182/blood.V71.1.65.65
Bodó I, 1999, Mutation causing dominant type 1 von Willebrand disease with high penetrance [abstract], Blood, 94, 373a
Miller CH, 1979, Genetics of classic von Willebrand’s disease: I. Phenotypic variation within families, Blood, 54, 117, 10.1182/blood.V54.1.117.117
Ørstavik KH, 1985, Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level, Am J Hum Genet, 37, 89
Veyradier A, 2000, Acquired von Willebrand syndrome: from pathophysiology to management, Thromb Haemost, 84, 175, 10.1055/s-0037-1613993
Gill JC, 1986, Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects, Blood, 67, 758, 10.1182/blood.V67.3.758.758
Mazzucconi MG, 1991, Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha‐2b recombinant interferon, Haemostasis, 21, 135
Silwer J, 1973, Von Willebrand’s disease in Sweden, Acta Paediatr Scand Suppl, 238, 1
Wahlberg T, 1980, Application of indicators, predictors and diagnostic indices in coagulation disorders: II. Evaluation of laboratory variables with continuous test results, Methods Inf Med, 19, 201, 10.1055/s-0038-1635280
Drews CD, 2002, Screening questions to identify women with von Willebrand disease, J Am Med Womens Assoc, 57, 217
Federici AB, 2004, A sensitive ristocetin co‐factor activity assay with recombinant glycoprotein Ibα for the diagnosis of patients with low von Willebrand factor levels, Haematologica, 89, 77
Vanhoorelbeke K, 2005, Plasma glycocalicin as a source of GPIbα in the von Willebrand factor ristocetin cofactor ELISA, Thromb Haemost, 93, 165, 10.1160/TH04-04-0402
Scott JP, 1991, The rapid differentiation of type IIb von Willebrand’s disease from platelet‐type (pseudo‐) von Willebrand’s disease by the ‘neutral’ monoclonal antibody binding assay, Am J Clin Pathol, 96, 723, 10.1093/ajcp/96.6.723
Federici AB, 2000, Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease: single center comparison of four different assays, Thromb Haemost, 84, 1127, 10.1055/s-0037-1614188
National Committee for Clinical Laboratory Standards (NCCLS), 2002, Assays of von Willebrand Factor Antigen and Ristocetin Cofactor Activity: Approved Guideline
Ginsburg D, 1999, Molecular genetics of von Willebrand disease, Thromb Haemost, 82, 585, 10.1055/s-0037-1615884
Montgomery RR, 2001, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 249
Montgomery RR, 1993, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 134
Van Genderen PJ, 1998, Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome, Thromb Haemost, 80, 495, 10.1055/s-0037-1615235
National Committee for Clinical Laboratory Standards (NCCLS), 2003, Collection, Transport, and Processing of Blood Specimens for Testing Plasma‐based Coagulation Assays: Approved Guideline
Favaloro EJ, 2001, Collection and transport of samples for laboratory testing in von Willebrand’s disease (VWD): time for a reappraisal, Thromb Haemost, 86, 1589, 10.1055/s-0037-1616773
Centers for Disease Control and Prevention, Bleeding and Clotting Disorders Surveillance [Homepage on the Internet]
Mannucci PM, 1997, Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years, Blood, 90, 2515, 10.1182/blood.V90.7.2515
Cash JD, 1974, Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I‐desamino‐8‐D‐arginine vasopressin, angiotensin and oxytocin in man, Br J Haematol, 27, 363
Rodeghiero F, 1989, Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A, Blood, 74, 199, 10.1182/blood.V74.6.1997.1997
Virtanen R, 2004, Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose of desmopressin, Thromb Haemost, 92, 1154, 10.1055/s-0037-1614294
Ruggeri ZM, 1982, Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand’s disease subtypes, Blood, 59, 1272, 10.1182/blood.V59.6.1272.1272
Casonato A, 1999, Post‐DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation, Thromb Haemost, 81, 224, 10.1055/s-0037-1614447
Kreuz W, 1994, Haemate P in children with von Willebrand’s disease, Haemostasis, 24, 304
Manno CS, 1998, Successful management of patients with type 1 von Willebrand’s disease with desmopressin acetate for tonsillectomy [abstract], Haemophilia, 4, 288
Hanna WT, 1994, The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease, Thromb Haemost, 71, 173
Lubetsky A, 1999, Safety and efficacy of continuous infusion of a combined factor VIII‐von Willebrand factor (vWF) concentrate (Haemate‐P) in patients with von Willebrand disease, Thromb Haemost, 81, 229, 10.1055/s-0037-1614448
Fowler WE, 1989, DDAVP for type IIB von Willebrand disease, Blood, 74, 1859, 10.1182/blood.V74.5.1859.1859
Humate‐P [package insert]. King of Prussia PA:CSL Behring 2007.
Alphanate SD/HT [package insert]. Los Angeles CA:Grifols 2007.
US Food and Drug Administration, Additional Standards for Human Blood and Blood Products
National Hemophilia Foundation, 2006, MASAC Document 177. MASAC Recommendations Concerning the Treatment of Hemophilia and other Bleeding Disorders (Revised October 2006) [Monograph on the Internet]
Scharrer I, 1994, Experience with Haemate P in von Willebrand’s disease in adults, Haemostasis, 24, 298
National Hemophilia Foundation, 2006, MASAC Recommendation #128: MASAC Recommendations for Hepatitis A and B Immunization of Individuals with Bleeding Disorders [Monograph on the Internet]
Barbui T, 1977, The aspirin tolerance test in von Willebrand’s disease, Thromb Haemost, 38, 510, 10.1055/s-0038-1651857
Arkel YS, 1994, Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin, Thromb Haemost, 72, 643, 10.1055/s-0038-1648928
Macik BG, 1988, The use of high‐dose intravenous gamma‐globulin in acquired von Willebrand syndrome, Arch Pathol Lab Med, 112, 143
Van Genderen PJ, 1995, High‐dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease, Thromb Haemost, 73, 891, 10.1055/s-0038-1653887
Rahmani R, 1990, Association of von Willebrand’s disease with plasma cell dyscrasia and gastrointestinal angiodysplasia, Isr J Med Sci, 26, 504
Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development, Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland, 1998, Effects of contraceptives on hemoglobin and ferritin, Contraception, 58, 262
Foster PA, 1995, The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey, Thromb Haemost, 74, 784, 10.1055/s-0038-1649813
Bottini E, 1991, Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia: case reports, Haematologica, 76, 431
Kadir RA, 1999, Women and inherited bleeding disorders: pregnancy and delivery, Semin Hematol, 36, 28
Lindoff C, 1993, Treatment with tranexamic acid during pregnancy, and the risk of thrombo‐embolic complications, Thromb Haemost, 70, 238, 10.1055/s-0038-1649475
Storm O, 1976, Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy [Danish], Ugeskr Laeger, 138, 1781
Howorka E, 1970, Effect of EACA administered to female rabbits during pregnancy on the fetuses [Polish], Patol Pol, 21, 311
Kassam SH, 1984, Sickle‐cell‐induced hematuria in pregnancy: the current diagnostic and therapeutic approach, J Reprod Med, 29, 117
Ross MG, 2002, Obstetrics: Normal and Problem Pregnancies, 37
Benedetti TJ, 2005, Obstetrics: Normal and Problem Pregnancies, 503
Lee CY, 1981, Ultrasonic evaluation of the postpartum uterus in the management of postpartum bleeding, Obstet Gynecol, 58, 227
Ruggeri ZM, 1982, Type IIB von Willebrand’s disease: differential clearance of endogenous versus transfused large multimer von Willebrand factor, Blood, 60, 1453, 10.1182/blood.V60.6.1453.1453
Conti M, 1986, Pregnancy in women with different types of von Willebrand disease, Obstet Gynecol, 68, 282
Department of Health and Human Services, Clinical Hematology Research Career Development Program [Homepage on the Internet]
National Hemophilia Foundation, 2006, The National Hemophilia Foundation Clinical Fellowship Program
Woods AI, 2001, Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand’s disease, Haematologica, 86, 420
Marder VJ, 1985, Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis, Thromb Haemost, 54, 871, 10.1055/s-0038-1660151
Mazurier C, 2001, Recommended abbreviations for von Willebrand factor and its activities, Thromb Haemost, 86, 712, 10.1055/s-0037-1616109
Rodeghiero F, 1996, Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A, Thromb Haemost, 76, 692, 10.1055/s-0038-1650645